Fig. 4: Alterations in serum ALT, AST, GGT, and ALP levels from baseline upon completion of the 28-day treatment in the NASH patients. | Nature Communications

Fig. 4: Alterations in serum ALT, AST, GGT, and ALP levels from baseline upon completion of the 28-day treatment in the NASH patients.

From: ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Fig. 4: Alterations in serum ALT, AST, GGT, and ALP levels from baseline upon completion of the 28-day treatment in the NASH patients.The alternative text for this image may have been generated using AI.

Bar graphs represented means with blue error bars reflecting standard deviation (SD) with absolute changes in ALT (a), AST (b), GGT (c), and ALP (d) levels from baseline as the dependent variable. Each gray dot represents an individual (each group, N = 9). Source data are provided as a Source Data file.

Back to article page